SCHEMBL1156837

SCHEMBL1156837

CO[CH]c1ccc(OC)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.58
CYP2A6 P11509 1/20 0.58
CA12 O43570 1/20 0.58
CA1 P00915 1/20 0.58
CA2 P00918 1/20 0.58
CA7 P43166 1/20 0.58
CA9 Q16790 1/20 0.58
CA14 Q9ULX7 1/20 0.58
KDM4E B2RXH2 4/20 0.56
CYP3A4 P08684 2/20 0.56
LMNA P02545 2/20 0.56
TP53 P04637 1/20 0.56
TSHR P16473 1/20 0.56
HPGD P15428 2/20 0.56
MAPT P10636 1/20 0.56
TRPA1 O75762 1/20 0.54
RELA Q04206 1/20 0.54
CYP1A2 P05177 3/20 0.52
CYP1A1 P04798 3/20 0.52
CYP1B1 Q16678 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4881152 0.78 RELA (0.81) ALDH1A1KDM4ECYP3A4LMNATP53
SCHEMBL699458 0.78 RELA (0.81) ALDH1A1KDM4ECYP3A4LMNATP53
SCHEMBL27883 0.78 CA12 (0.65) ALDH1A1CYP2A6CA12CA1CA2
SCHEMBL14950253 0.78 RELA (0.81) ALDH1A1KDM4ECYP3A4LMNATP53
SCHEMBL699457 0.78 RELA (0.81) ALDH1A1KDM4ECYP3A4LMNATP53
SCHEMBL631998 0.78 RELA (0.81) ALDH1A1KDM4ECYP3A4LMNATP53
SCHEMBL13790336 0.78 RELA (0.81) ALDH1A1KDM4ECYP3A4LMNATP53
1,4-Dimethoxybenzene SCHEMBL8489 0.76 CA1 (1.00) ALDH1A1CYP2A6CA12CA1CA2
1,4-Dimethoxybenzene SCHEMBL21802643 0.76 CA1 (1.00) ALDH1A1CYP2A6CA12CA1CA2
SCHEMBL97603 0.76 KDM4E (0.65) ALDH1A1CYP2A6CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101754956-B Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2014-04-23 CN claimed
CN-101663287-B Semi-synthetic process for the preparation of taxane derivatives CHATHAM BIOTEC LTD 2013-06-19 CN claimed
US-8299279-B2 Semi-synthetic process for the preparation of taxane derivatives CHATHAM BIOTEC LTD. (CA) 2012-10-30 US claimed
CN-101754956-A Substituted indazole derivatives active as kinase inhibitors NERVIANO MEDICAL SCIENCES SRL 2010-06-23 CN claimed
CN-101663287-A Semi-synthetic process for the preparation of taxane derivatives CHATHAM BIOTEC LTD 2010-03-03 CN claimed
US-20100029957-A1 Semi-Synthetic Process for the Preparation of Taxane Derivatives CHATHAM BRUNSWICK BIOTEC LTD (CA) 2010-02-04 US claimed
EP-2114908-A1 SEMI-SYNTHETIC PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES Chatham Biotec Ltd (CA) 2009-11-11 EP claimed
WO-2008090368-A1 SEMI-SYNTHETIC PROCESS FOR THE PREPARATION OF TAXANE DERIVATIVES CHATHAM BIOTEC LTD (CA) 2008-07-31 WO claimed
US-6605590-B1 Essential amino acids, nutrients, oligopeptides NOVUS INTERNATIONAL, INC. 2003-08-12 US claimed
EP-0292808-B1 Substituted vinyl cephalosporins, process for their preparation and their use as medicines BAYER AG (DE) 1994-03-02 EP claimed
US-4849531-A Process for the preparation of 2,3-epoxyamides BAYER AKTIENGESELLSCHAFT (DE) 1989-07-18 US claimed
EP-0292808-A2 Substituted vinyl cephalosporins, process for their preparation and their use as medicines BAYER AG (DE) 1988-11-30 EP claimed
EP-0244717-A2 Process for the preparation of 2,3-epoxyamides BAYER AG (DE) 1987-11-11 EP claimed
CN-118234628-A Thermosensitive recording medium 日本制纸株式会社 2024-06-21 CN disclosed
US-20240190156-A1 THERMOSENSITIVE RECORDING MEDIUM NIPPON PAPER INDUSTRIES CO., LTD. (JP) 2024-06-13 US disclosed
US-11912052-B2 Thermosensitive recording medium NIPPON PAPER INDUSTRIES CO., LTD. 2024-02-27 US disclosed
US-4849531-A Process for the preparation of 2,3-epoxyamides BAYER AKTIENGESELLSCHAFT (DE) 1989-07-18 US disclosed
EP-0292808-A2 Substituted vinyl cephalosporins, process for their preparation and their use as medicines BAYER AG (DE) 1988-11-30 EP disclosed
EP-0284954-A2 Cephalosporinderivatives, process for their preparation and their use in pharmaceutical products BAYER AG (DE) 1988-10-05 EP disclosed
EP-0244717-A2 Process for the preparation of 2,3-epoxyamides BAYER AG (DE) 1987-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029957-A1 Semi-Synthetic Process for the Preparation of Taxane Derivatives WEE1, WEE2, NOTUM ALDH1A1 3681/4885CYP2A6 435/4885CA12 3542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.